Geode Capital Management LLC Increases Holdings in Viking Therapeutics, Inc. $VKTX

Posted by Brenda Bartman on Jun 9th, 2026

Geode Capital Management LLC lifted its position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 24.0% in the fourth quarter, Holdings Channel reports. The firm owned 1,994,509 shares of the biotechnology company’s stock after buying an additional 385,903 shares during the period. Geode Capital Management LLC’s holdings in Viking Therapeutics were worth $70,183,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of VKTX. Raleigh Capital Management Inc. boosted its holdings in shares of Viking Therapeutics by 58.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 347 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viking Therapeutics in the third quarter valued at approximately $38,000. Fifth Third Bancorp boosted its holdings in shares of Viking Therapeutics by 169.3% in the fourth quarter. Fifth Third Bancorp now owns 1,077 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 677 shares during the period. Lodestone Wealth Management LLC purchased a new stake in shares of Viking Therapeutics in the fourth quarter valued at approximately $39,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Viking Therapeutics by 71.0% in the fourth quarter. GAMMA Investing LLC now owns 1,195 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 496 shares during the period. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Stock Up 2.8%

Viking Therapeutics stock opened at $29.24 on Tuesday. Viking Therapeutics, Inc. has a twelve month low of $22.96 and a twelve month high of $43.15. The business has a fifty day moving average of $32.17 and a two-hundred day moving average of $33.03. The firm has a market cap of $3.40 billion, a P/E ratio of -7.06 and a beta of 0.69.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.36). During the same quarter in the previous year, the firm posted ($0.41) earnings per share. Equities analysts expect that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VKTX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Monday, March 23rd. Lake Street Capital started coverage on Viking Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $89.00 target price for the company. Truist Financial started coverage on Viking Therapeutics in a report on Wednesday, May 27th. They set a “buy” rating and a $83.00 target price for the company. BTIG Research restated a “buy” rating and set a $125.00 target price on shares of Viking Therapeutics in a report on Friday, May 1st. Finally, Morgan Stanley set a $95.00 target price on Viking Therapeutics in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.60.

Read Our Latest Stock Analysis on Viking Therapeutics

About Viking Therapeutics

(Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.